Provided by Tiger Trade Technology Pte. Ltd.

Pacira Pharmaceuticals

25.36
+0.20000.79%
Post-market: 25.360.00000.00%19:30 EDT
Volume:538.04K
Turnover:13.66M
Market Cap:1.01B
PE:72.09
High:25.57
Open:25.43
Low:25.18
Close:25.16
52wk High:27.66
52wk Low:18.80
Shares:39.86M
Float Shares:36.37M
Volume Ratio:0.97
T/O Rate:1.48%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.3518
EPS(LYR):0.1578
ROE:2.05%
ROA:1.48%
PB:1.50
PE(LYR):160.68

Loading ...

Barclays Sticks to Its Hold Rating for Pacira Pharmaceuticals (PCRX)

TIPRANKS
·
May 14

Doma Perpetual Capital Management Calls For Removal Of Pacira CEO And Strategic Sale

Reuters
·
May 13

Doma Perpetual: Nominates Eric De Armas, Christopher Dennis, and Oliver Benton Curtis Iii to Pacira Board

THOMSON REUTERS
·
May 13

Doma Perpetual: Owns About 7.5% of Pacira Biosciences

THOMSON REUTERS
·
May 13

Doma Perpetual Capital Management: Calls for Removal of Pacira CEO and Strategic Sale

THOMSON REUTERS
·
May 13

Pacira BioSciences to join RBC Capital Markets healthcare conference fireside chat

Reuters
·
May 13

BRIEF-Pacira Biosciences Sends Letter To Stockholders Reiterating Superior Qualifications Of Its Board Nominees

Reuters
·
May 13

Pacira urges vote for board slate as activist DOMA pushes CEO ouster, sale process

Reuters
·
May 13

Pacira Biosciences Sends Letter to Stockholders Reiterating Superior Qualifications of Its Board Nominees

THOMSON REUTERS
·
May 13

Pacira grants inducement equity awards to new hires, options priced at $24.69

Reuters
·
May 08

Pacira Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
May 08

Pacira urges vote for board slate, rejects activist DOMA push for CEO change, sale talks

Reuters
·
May 06

Stock Track | Pacira Pharmaceuticals Plummets 5.57% Intraday After Q1 Earnings Decline and Maintained Forecast

Stock Track
·
May 01

Analysts’ Top Healthcare Picks: Pacira Pharmaceuticals (PCRX), Cadrenal Therapeutics, Inc. (CVKD)

TIPRANKS
·
May 01

RBC Raises Price Target on Pacira Biosciences to $24 From $22, Keeps Sector Perform Rating

MT Newswires Live
·
May 01

Stock Track | Pacira Pharmaceuticals Soars 5.41% Intraday on Strong Q1 Earnings Beat, Revenue Growth and Maintained Buy Rating

Stock Track
·
May 01

Stock Track | Pacira Pharmaceuticals Soars 5.10% in Pre-Market on Strong Q1 Results and Maintained Buy Rating

Stock Track
·
May 01

Pacira BioSciences Is Maintained at Buy by Needham

Dow Jones
·
May 01

Pacira Q1 revenue beats estimates, co raises 2026 outlook

Reuters
·
May 01

Pacira reports Q1 EPS 60c, consensus 56c

TIPRANKS
·
May 01